Study wrapper · #290
Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.
Editor's note
This is the bioRxiv preprint reporting the same 5xFAD experiment as the peer-reviewed version elsewhere in this collection — and, importantly, it has not yet completed peer review. Researchers gave intranasal GHK-Cu (15 mg/kg, three times weekly for three months) to male and female Alzheimer's-model mice and reported delayed cognitive impairment, reduced amyloid plaques and lower brain inflammation in the frontal cortex and hippocampus. The stated rationale — that a multi-pathway agent may outperform single-target drugs in a multifactorial disease — is reasonable, and inclusion of both sexes is a design strength. The core caveats are unchanged: 5xFAD is an engineered amyloid-overexpressing model whose benefits often fail to translate to human Alzheimer's, and there are no human data for GHK-Cu in cognition. As a preprint, the results have not been independently vetted. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
This is a preprint — a research report shared before formal peer review — describing a study in mice. Because many drug targets have failed against Alzheimer's, the researchers argued that a treatment hitting several pathways at once might work better. GHK-Cu, a copper-bound natural peptide, has anti-inflammatory and antioxidant effects and has been reported to improve thinking in older mice. Male and female 5xFAD mice (engineered to develop amyloid buildup like Alzheimer's) received GHK-Cu sprayed into the nose (15 mg per kg) three times a week for three months, starting at four months old. Compared with untreated mice, treated animals declined more slowly on memory tasks, had fewer amyloid plaques, and showed less inflammation in memory-related brain areas. The authors say more studies are warranted. Two cautions matter: the results have not yet been peer-reviewed, and the mouse model only partly resembles human Alzheimer's, so these findings cannot show whether GHK-Cu would help people. The abstract did not report side effects.